

Resource Summary Report

Generated by NIF on Aug 1, 2026

PE/Cyanine7 anti-human CD137 (4-1BB)

RRID:AB_2207741

Type: Antibody

Proper Citation

BioLegend Cat# 309818, RRID:AB_2207741

Antibody Information

URL: http://antibodyregistry.org/AB_2207741

Proper Citation: BioLegend Cat# 309818, RRID:AB_2207741

Target Antigen: CD137

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-human CD137 (4-1BB)

Description: This monoclonal targets CD137

Target Organism: human

Clone ID: Clone 4B4-1

Antibody ID: AB_2207741

Vendor: BioLegend

Catalog Number: 309818

Alternative Catalog Numbers: 309817

Record Creation Time: 20250819T235542+0000

Record Last Update: 20250820T065104+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human CD137 (4-1BB).

No alerts have been found for PE/Cyanine7 anti-human CD137 (4-1BB).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Jones RD, et al. (2026) Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells. *Cell stem cell*, 33(1), 73.

Gonnella G, et al. (2025) Immune profiling in subclinical secondary dengue-infected cases reveals adaptive immune signatures correlated to protection from severe dengue. *Cell host & microbe*, 33(7), 1191.

Schweihofer V, et al. (2025) Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma. *Frontiers in oncology*, 15, 1622008.

Kobiyama K, et al. (2025) Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox. *EBioMedicine*, 115, 105703.

Müller TR, et al. (2024) Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. *Cell host & microbe*, 32(2), 156.

Zhang Y, et al. (2024) Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy. *Cell reports methods*, 4(9), 100843.

Adamo S, et al. (2023) Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. *Cell host & microbe*, 31(6), 928.

Andreas N, et al. (2022) Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination. *Vaccines*, 10(1).

Eiva MA, et al. (2022) Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs. *European journal of immunology*, 52(1), 96.

Nogimori T, et al. (2022) Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. *Frontiers in immunology*, 13, 1081047.

Menges D, et al. (2022) Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. *Nature communications*, 13(1), 4855.

Schnizer C, et al. (2022) Persistent humoral and CD4+ TH cell immunity after mild SARS-CoV-2 infection-The CoNAN long-term study. *Frontiers in immunology*, 13, 1095129.

Gao Y, et al. (2022) Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. *Immunity*, 55(9), 1732.

Quiros-Fernandez I, et al. (2021) Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals. *EBioMedicine*, 72, 103610.

Thieme CJ, et al. (2020) Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. *Cell reports. Medicine*, 1(6), 100092.